ImmuPharma (LON:IMM) Trading 34.1% Higher - Still a Buy?

Key Points

• ImmuPharma's shares surged by 34.1%, reaching a high of GBX 11.50 ($0.16) during trading, indicating significant market interest and increased trading volume.
• The company's recent earnings report revealed a negative EPS of GBX (0.38), with analysts forecasting earnings of -339.00 for the current fiscal year.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, aiming to treat Lupus and potentially other conditions.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) shot up 34.1% during trading on Tuesday . The company traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). 57,593,953 shares were traded during trading, an increase of 656% from the average session volume of 7,620,919 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Trading Up 34.1%

The firm has a market capitalization of £54.02 million, a PE ratio of -1,214.61 and a beta of 1.53. The firm has a 50-day moving average of GBX 2.38 and a two-hundred day moving average of GBX 2.70.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.